{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:42:55Z","timestamp":1791398575679,"version":"4.3.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04443-7","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:15:35Z","timestamp":1780658135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhanced PD-L1 targeting boosts the cytotoxic activity of FOLR1- CAR NK92 cells against ovarian cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Xuena","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhe","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"14","key":"4443_CR1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","volume":"334","author":"G Caruso","year":"2025","unstructured":"Caruso G, Weroha SJ, Cliby W (2025) Ovarian cancer: a review. JAMA 334(14):1278\u20131291. https:\/\/doi.org\/10.1001\/jama.2025.9495","journal-title":"JAMA"},{"issue":"6","key":"4443_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following car t cell therapy: what we know so far. Nat Rev Clin Oncol 20(6):359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nat Rev Clin Oncol"},{"key":"4443_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020333","author":"J Daigre","year":"2024","unstructured":"Daigre J, Martinez-Osuna M, Bethke M et al (2024) Preclinical evaluation of novel folate receptor 1-directed car t cells for ovarian cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers16020333","journal-title":"Cancers"},{"issue":"12","key":"4443_CR4","doi-asserted-by":"publisher","first-page":"e13727","DOI":"10.1111\/cpr.13727","volume":"57","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhang M, Shen X et al (2024) Mesothelin car-engineered nk cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals. Cell Prolif 57(12):e13727. https:\/\/doi.org\/10.1111\/cpr.13727","journal-title":"Cell Prolif"},{"key":"4443_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008179","author":"NP Casey","year":"2024","unstructured":"Casey NP, Kleinmanns K, Forcados C et al (2024) Efficient car t cell targeting of the ca125 extracellular repeat domain of muc16. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-008179","journal-title":"J Immunother Cancer"},{"key":"4443_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012822","author":"D Salas-Benito","year":"2025","unstructured":"Salas-Benito D, Birocchi F, Park S et al (2025) Tandem car-t cells targeting mesothelin and muc16 overcome tumor heterogeneity by targeting one antigen at a time. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2025-012822","journal-title":"J Immunother Cancer"},{"issue":"8","key":"4443_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/CJI.0000000000000286","volume":"42","author":"X Ao","year":"2019","unstructured":"Ao X, Yang Y, Li W et al (2019) Anti-\u03b1fr car-engineered nk-92 cells display potent cytotoxicity against \u03b1fr-positive ovarian cancer. J Immunother 42(8):284\u2013296. https:\/\/doi.org\/10.1097\/CJI.0000000000000286","journal-title":"J Immunother"},{"key":"4443_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1610255","author":"JA Wik","year":"2025","unstructured":"Wik JA, Berge ER, Stromsnes K, Sk\u00e5lhegg BS (2025) Metabolism in the tumor microenvironment: implications for pathogenesis and therapeutics. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1610255","journal-title":"Front Immunol"},{"key":"4443_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125524","author":"A Smolarska","year":"2025","unstructured":"Smolarska A, Kokoszka Z, Naliwajko M et al (2025) Cell-based therapies for solid tumors: challenges and advances. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26125524","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4443_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"J Cha","year":"2019","unstructured":"Cha J, Chan L, Li C et al (2019) Mechanisms controlling pd-l1 expression in cancer. Mol Cell 76(3):359\u2013370. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.030","journal-title":"Mol Cell"},{"issue":"8","key":"4443_CR11","doi-asserted-by":"publisher","first-page":"103666","DOI":"10.1016\/j.drudis.2023.103666","volume":"28","author":"Z Peng","year":"2023","unstructured":"Peng Z, Li M, Li H, Gao Q (2023) Pd-1\/pd-l1 immune checkpoint blockade in ovarian cancer: dilemmas and opportunities. Drug Discov Today 28(8):103666. https:\/\/doi.org\/10.1016\/j.drudis.2023.103666","journal-title":"Drug Discov Today"},{"issue":"9","key":"4443_CR12","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko K, Matsumura N, Hamanishi J et al (2015) Ifn-\u03b3 from lymphocytes induces pd-l1 expression and promotes progression of ovarian cancer. Br J Cancer 112(9):1501\u20131509. https:\/\/doi.org\/10.1038\/bjc.2015.101","journal-title":"Br J Cancer"},{"issue":"9","key":"4443_CR13","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M et al (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating cd8+ t lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 104(9):3360\u20133365. https:\/\/doi.org\/10.1073\/pnas.0611533104","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4443_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L et al (2021) Regulation of pd-l1 expression in the tumor microenvironment. J Hematol Oncol 14(1):10. https:\/\/doi.org\/10.1186\/s13045-020-01027-5","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4443_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13048-025-01755-7","volume":"18","author":"B Pan","year":"2025","unstructured":"Pan B, Zheng X, Huang Y et al (2025) The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors. J Ovarian Res 18(1):175. https:\/\/doi.org\/10.1186\/s13048-025-01755-7","journal-title":"J Ovarian Res"},{"issue":"6","key":"4443_CR16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","volume":"19","author":"K Abiko","year":"2013","unstructured":"Abiko K, Mandai M, Hamanishi J et al (2013) PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 19(6):1363\u20131374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2199","journal-title":"Clin Cancer Res"},{"issue":"19","key":"4443_CR17","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99(19):12293\u201312297. https:\/\/doi.org\/10.1073\/pnas.192461099","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4443_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","volume":"65","author":"F Hirano","year":"2005","unstructured":"Hirano F, Kaneko K, Tamura H et al (2005) Blockade of B7\u2013H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65(3):1089\u20131096","journal-title":"Cancer Res"},{"issue":"10","key":"4443_CR19","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","volume":"22","author":"M Mandai","year":"2016","unstructured":"Mandai M, Hamanishi J, Abiko K et al (2016) Dual faces of IFN\u03b3 in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res 22(10):2329\u20132334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0224","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4443_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41416-022-01960-x","volume":"128","author":"K Abiko","year":"2023","unstructured":"Abiko K, Hamanishi J, Matsumura N, Mandai M (2023) Dynamic host immunity and PD-L1\/PD-1 blockade efficacy: developments after \u201cIFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.\u201d Br J Cancer 128(3):461\u2013467. https:\/\/doi.org\/10.1038\/s41416-022-01960-x","journal-title":"Br J Cancer"},{"issue":"1","key":"4443_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41408-024-01050-6","volume":"14","author":"SA Stefa\u0144czyk","year":"2024","unstructured":"Stefa\u0144czyk SA, Hagelstein I, Lutz MS et al (2024) Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7\u2013H3) antibody. Blood Cancer J 14(1):67. https:\/\/doi.org\/10.1038\/s41408-024-01050-6","journal-title":"Blood Cancer J"},{"issue":"22","key":"4443_CR22","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1182\/blood-2016-12-753830","volume":"129","author":"TS Rubin","year":"2017","unstructured":"Rubin TS, Zhang K, Gifford C et al (2017) Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH. Blood 129(22):2993\u20132999. https:\/\/doi.org\/10.1182\/blood-2016-12-753830","journal-title":"Blood"},{"issue":"8","key":"4443_CR23","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J et al (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126(8):3130\u20133144. https:\/\/doi.org\/10.1172\/JCI83092","journal-title":"J Clin Invest"},{"issue":"9","key":"4443_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ et al (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36(9):847\u2013856. https:\/\/doi.org\/10.1038\/nbt.4195","journal-title":"Nat Biotechnol"},{"key":"4443_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002500","author":"M Bajor","year":"2022","unstructured":"Bajor M, Graczyk-Jarzynka A, Marhelava K et al (2022) Pd-l1 car effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002500","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4443_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah E, Lin M, Silva-Benedict A et al (2016) T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res 4(6):498\u2013508. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0231","journal-title":"Cancer Immunol Res"},{"key":"4443_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep32488","author":"N Gennet","year":"2016","unstructured":"Gennet N, Tamburini C, Nan X, Li M (2016) Folr1: a novel cell surface marker for isolating midbrain dopamine neural progenitors and nascent dopamine neurons. Sci Rep-Uk. https:\/\/doi.org\/10.1038\/srep32488","journal-title":"Sci Rep-Uk"},{"key":"4443_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121802","author":"P Varaganti","year":"2023","unstructured":"Varaganti P, Buddolla V, Lakshmi BA, Kim Y (2023) Recent advances in using folate receptor 1 (folr1) for cancer diagnosis and treatment, with an emphasis on cancers that affect women. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2023.121802","journal-title":"Life Sci"},{"issue":"1","key":"4443_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-019-1074-3","volume":"18","author":"F Xie","year":"2019","unstructured":"Xie F, Xu M, Lu J et al (2019) The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol Cancer 18(1):146. https:\/\/doi.org\/10.1186\/s12943-019-1074-3","journal-title":"Mol Cancer"},{"key":"4443_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105741","author":"H Ying","year":"2021","unstructured":"Ying H, Zhang X, Duan Y et al (2021) Non-cytomembrane pd-l1: an atypical target for cancer. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2021.105741","journal-title":"Pharmacol Res"},{"issue":"1","key":"4443_CR31","doi-asserted-by":"publisher","first-page":"1777651","DOI":"10.1080\/2162402X.2020.1777651","volume":"9","author":"LM Reindl","year":"2020","unstructured":"Reindl LM, Albinger N, Bexte T et al (2020) Immunotherapy with NK cells: recent developments in gene modification open up new avenues. Oncoimmunology 9(1):1777651. https:\/\/doi.org\/10.1080\/2162402X.2020.1777651","journal-title":"Oncoimmunology"},{"issue":"2","key":"4443_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/aps.2017.125","volume":"39","author":"Y Hu","year":"2018","unstructured":"Hu Y, Tian Z, Zhang C (2018) Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin 39(2):167\u2013176. https:\/\/doi.org\/10.1038\/aps.2017.125","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"4443_CR33","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s00262-022-03192-7","volume":"71","author":"N Chovatiya","year":"2022","unstructured":"Chovatiya N, Kaur K, Huerta-Yepez S et al (2022) Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity. Cancer Immunol Immunother 71(12):2929\u20132941. https:\/\/doi.org\/10.1007\/s00262-022-03192-7","journal-title":"Cancer Immunol Immunother"},{"key":"4443_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030660","author":"R Klapdor","year":"2019","unstructured":"Klapdor R, Wang S, Morgan M et al (2019) Characterization of a novel third-generation anti-cd24-car against ovarian cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20030660","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4443_CR35","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1016\/j.ymthe.2024.01.027","volume":"32","author":"K Wang","year":"2024","unstructured":"Wang K, Wang L, Wang Y et al (2024) Reprogramming natural killer cells for cancer therapy. Mol Ther 32(9):2835\u20132855. https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.027","journal-title":"Mol Ther"},{"issue":"1","key":"4443_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-023-00431-0","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhou W, Yang J et al (2023) Chimeric antigen receptor engineered natural killer cells for cancer therapy. Exp Hematol Oncol 12(1):70. https:\/\/doi.org\/10.1186\/s40164-023-00431-0","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"4443_CR37","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jcyt.2025.06.006","volume":"27","author":"S Rana","year":"2025","unstructured":"Rana S, Thomas L, Kirkham AM et al (2025) CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials. Cytotherapy 27(10):1179\u20131189. https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.006","journal-title":"Cytotherapy"},{"issue":"15","key":"4443_CR38","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/1750743X.2025.2582464","volume":"17","author":"HC Cochran","year":"2025","unstructured":"Cochran HC, Ghobadi KA, Ghobadi A (2025) Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy. Immunotherapy 17(15):1115\u20131127. https:\/\/doi.org\/10.1080\/1750743X.2025.2582464","journal-title":"Immunotherapy"},{"issue":"6","key":"4443_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382(6):545\u2013553. https:\/\/doi.org\/10.1056\/NEJMoa1910607","journal-title":"N Engl J Med"},{"issue":"3","key":"4443_CR40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R et al (2024) Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med 30(3):772\u2013784. https:\/\/doi.org\/10.1038\/s41591-023-02785-8","journal-title":"Nat Med"},{"issue":"10522","key":"4443_CR41","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/S0140-6736(25)01671-X","volume":"406","author":"J Gao","year":"2026","unstructured":"Gao J, Li M, Sun M et al (2026) Efficacy and safety of allogeneic cd19 car nk-cell therapy in Systemic Lupus Erythematosus: a case series in China. Lancet 406(10522):2968\u20132979. https:\/\/doi.org\/10.1016\/S0140-6736(25)01671-X","journal-title":"Lancet"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04443-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04443-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04443-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T03:25:15Z","timestamp":1786418715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04443-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4443"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04443-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the use of human subjects was obtained from the Research Ethics Committee of Daping Hospital (Chongqing, China), which granted a waiver of informed consent (2025\u2013414). The animal study was approved by the Ethics Committee of the Army Medical University (AMUWEC20257044).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"204"}}